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Abstract
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Background

Human insulin degrading enzyme (IDE) plays a role in the proteolytic

v Two key conformational
switches open and closed
transition in absence of
substrate
v Partly open allow smaller
substrates peptides
(bradykinin) fully open larger
substrates such as insulin
v Dimeric IDE structure. The
key features of IDE including
IDE-N, IDE-C, catalytic zinc
ion, and door subdomain, are
colored in cyan, green, gray,
and red, respectively, while
the surface of catalytic
chamber of IDE is in gray

cleavage of insulin, glucagon, and other short, hydrophobic peptides with
roles in glucose and cellular metabolism. Because of IDE’s role in insulin
clearance, IDE inhibitors may hold promise as therapies for potentiating
insulin signaling in patients suffering from type 2 diabetes mellitus. IDE is
a large (~100 kDa) chambered protease of the conserved M16A
subfamily of zinc metalloproteases. The enzyme adopts a structure that
is analogous to a clamshell formed by the joining of the N terminal and C
terminal domains. The characteristic zinc binding and catalytic motif
(HXXEH) is positioned within the enzyme’s N terminus, while C terminal
residues also play important roles in substrate binding and catalysis.
Here, we describe the use of a computational work-flow for identifying
novel IDE inhibitors. The work flow integrates mutation-based active site
structural analysis, virtual screening, docking and fragment-based
design. Initial computational results appear promising and should lead to

Trends in Endocrinology &
Metabolism 2016 27, 24-34DOI:
(10.1016/j.tem.2015.11.003,

assay testing in the near future.

Introduction
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v Insulin-degrading enzyme (IDE) a 110 kDa zinc metalloprotease is
involved in the clearance of many bioactive peptide substrates,
including insulin (Km = 85 nM) and amyloid-beta, peptides vital to the
development of diabetes and Alzheimer's disease, respectively
v Located in the cytosol its proteolytic activity subject to complicated
signaling regulation inside of cells
v The role of IDE in the clearance of insulin suggests that IDE
inhibitors could be used moderate levels of insulin in type 2 patients
v The IDE active site consists of two clamshell like structure
connected by a liker which is flexible allowing “open and closed
state” which allows access to the catalytic zinc
v Large active site called crypt ~ 15,700 Å
v IDE can exist in solution as monomer and then aggregates to its
most active form the dimer
v When the enzyme opens the enzyme encapsulates the substrate
that primarily bind to an exosite 30 Å away

J. Mol. Biol. 395, 430-443 (2010), J Biol Chem. 2015 Aug 14;290(33):20044-59, Trends in Endocrinology &
Metabolism 2016 27, 24-34DOI: (10.1016/j.tem.2015.11.003, Eur J Med Chem. 2015 January 27; 90: 547–567

Molecular Docking
Virtual Libraries based
on physical properties
from Zinc Database
Docking
Software
Vega-ZZ
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Active Site

v
v
v
v
v
v

Known 60 nM inhibitor crystal structure used
Forms close contacts at catalytic site with IDE-N, IDE-C
Chelates to zinc ion with hydroxamate
Fluorine group form π stacking interaction with Phe820
Triazole interacts with Arg824
Naphthyl group hydrophobic interactions F820, F834

Known Inhibitors

Zinc Database

Figure 3 Pose of docked potential
inhibitor with crystal structure
Figure 4 IDE inhibitor at active site
ligand(gold), metal zinc (green)
gray hydrophobic area
v Rationally design virtual library based on Lipinski’s Rules
molecular weight, log P, and other criteria
v Test only compounds that can be purchased with the
selected compounds to be tested on just the
target/enzyme
v When pharmaceutical hit is found it can be drawn to find
congeners for further optimization
.J. Chem. Inf. Model., 2015, 55 (11), pp 2324–2337
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Results

Nature
Communication
s volume 6,
Article number:
8250 (2015)
doi:10.1038/nc
omms9250
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Results
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Predicted ligand poses
and binding affinities
rescoring using four other
criteria

Generates poses and ΔG’s
Each virtual compound has ten different poses
Sort out duplicates between the five different binding criteria
Compare pose to crystal ligand pose
Analyze distance of docked ligand and metal in enzyme
Look for hydrogen bonding interactions
Analyze fit in binding pockets look for cavities in enzyme
Look for acceptable pose buy compound test on in vitro assay
Generate pharmacological hit
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v Top 5% of virtual
compounds are
summarized in excel
sheet
v Each virtual compound
10 different
conformations
v Excel computes
duplicates from the five
different criteria that
evaluates virtual
docking studies

Figure 2 Pose of both docked
ligand and crystal structure
inhibitor (gold) from protein
model

Protein-Receptor
v
v
v
v
v
v
v
v
v
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Figure 1 Pose of docked ligand
showing the distance with the metal
zinc (green) look for distances < 2.5 Å

Leissring,J. Med. Chem., 2013, 56 (6), pp 2246–2255, Nat Commun. 2015 Sep 23;6:8250, J Biol Chem. 2015 Aug
14;290(33):20044-59, Eur J Med Chem. 2015 January 27; 90: 547–567, Nature volume 511, pages 94–98 (03 July 2014)
.
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Results

Table 1 Different parameters
applied for the docking studies

Potential IDE inhibitor
Figure 5 Pose of docked potential
inhibitor at the binding pocket showing
cavities

Results
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v Active site of IDE
very large 15,700
Å cavities to build
into
v Generate virtual
compound library
of congeners of
known IDE
inhibitors
v Generate virtual
compound library
of higher
molecular weights

Figure 6 IDE inhibitor (white) at active site showing potential hydrogen
bonding with SER 138, amino acids: shades of blue non-polar, green
polar, brown charged.

Conclusion
Future Work
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v Using physical properties for the ligands, multiple parameters for
docking studies allows smaller more manageable libraries/ data
v Biological assay/testing of the interesting compounds from docking
studies to be evaluated in vitro on the target enzyme
v Initial identification of the pharmaceutical hit optimize via virtual
compounds
v Identification of the pharmacophore
v Site directed mutagenesis studies
v Looking for biological clues that will drive the synthetic chemistry
v Are there cavities in the enzyme that can be build into
v Find new hydrogen bonding interactions
v Fragment based drug design
v Generate synthetic schemes to generate congeners of the
pharmaceutical hit
v Continue molecular modeling to support synthetic chemistry
v Evaluate pharmacokinetics ADME
1

